Triple
T20301097
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Imfinzi |
E505480
|
entity |
| Predicate | hasGenericName |
P23148
|
FINISHED |
| Object |
durvalumab
Durvalumab is a human monoclonal antibody immunotherapy drug that targets the PD-L1 protein to help the immune system attack certain types of cancer.
|
E1423943
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: durvalumab | Statement: [Imfinzi, hasGenericName, durvalumab]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: durvalumab Context triple: [Imfinzi, hasGenericName, durvalumab]
-
A.
nivolumab
Nivolumab is a monoclonal antibody immunotherapy drug that blocks the PD-1 immune checkpoint to enhance the body’s anti-tumor response in various cancers.
-
B.
avelumab
Avelumab is a human monoclonal antibody immunotherapy drug used to treat certain cancers by blocking the PD-L1 immune checkpoint pathway.
-
C.
Libtayo
Libtayo is a monoclonal antibody immunotherapy drug used primarily to treat certain types of advanced skin and lung cancers by targeting the PD-1 pathway.
-
D.
daratumumab
Daratumumab is a monoclonal antibody drug used primarily to treat multiple myeloma by targeting and destroying malignant plasma cells.
-
E.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: durvalumab Triple: [Imfinzi, hasGenericName, durvalumab]
Generated description
Durvalumab is a human monoclonal antibody immunotherapy drug that targets the PD-L1 protein to help the immune system attack certain types of cancer.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: durvalumab Target entity description: Durvalumab is a human monoclonal antibody immunotherapy drug that targets the PD-L1 protein to help the immune system attack certain types of cancer.
-
A.
nivolumab
Nivolumab is a monoclonal antibody immunotherapy drug that blocks the PD-1 immune checkpoint to enhance the body’s anti-tumor response in various cancers.
-
B.
avelumab
Avelumab is a human monoclonal antibody immunotherapy drug used to treat certain cancers by blocking the PD-L1 immune checkpoint pathway.
-
C.
Libtayo
Libtayo is a monoclonal antibody immunotherapy drug used primarily to treat certain types of advanced skin and lung cancers by targeting the PD-1 pathway.
-
D.
daratumumab
Daratumumab is a monoclonal antibody drug used primarily to treat multiple myeloma by targeting and destroying malignant plasma cells.
-
E.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e0b4b8ab648190906e18538c250148 |
completed | April 16, 2026, 10:06 a.m. |
| NER | Named-entity recognition | batch_69e6770c700c81909da247cef0d0f1eb |
completed | April 20, 2026, 6:57 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_6a08611762e481909ee2f41434c86aa5 |
completed | May 16, 2026, 12:20 p.m. |
| NEDg | Description generation | batch_6a0863506f4481909c106c49f6b71191 |
completed | May 16, 2026, 12:30 p.m. |
| NED2 | Entity disambiguation (via description) | batch_6a0863f4bb788190b6ef1fe57279badb |
completed | May 16, 2026, 12:32 p.m. |
Created at: April 16, 2026, 11:17 a.m.